Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about ICGEB, Indian institute sheds light on immune response in Dengue
India has the highest numbers of dengue infections of any country. So far this year, over 51,730 cases of dengue cases have been reported in India, 2,333 in Delhi alone, but the actual estimated numbers might be ten times higher. Despite this emerging problem, there has been little work towards understanding the immune responses in Indians infected with the dengue virus.
- Read more about Novel cancer drug pass through blood-brain barrier
In efforts to develop new treatments for brain cancer, scientists from Johns Hopkins Drug Discovery and the Kimmel Cancer Center's Bloomberg~Kimmel Institute for Cancer Immunotherapy report they have altered the structure of an experimental drug that seems to enhance its ability to slip through the mostly impermeable blood-brain barrier.
- Read more about Sobi's SOBI003 get European Orphan Drug status to treat MPS IIIA
Swedish Orphan Biovitrum AB (publ) (Sobi) has been granted orphan designation by the European Commission (EC) for the company’s development product candidate SOBI003, a chemically modified human recombinant sulfamidase for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo A syndrome). SOBI003 will be included in the EU Community Register of Orphan Medicinal Products.

(adsbygoogle = window.adsbygoogle || []).push({});
- Read more about Keystone Nano get US FDA orphan drug status for Ceramides to treat liver cancer
Keystone Nano, a company is working at the interface between nanotechnology and the life sciences, has received orphan drug status for the use of Ceramide to treat liver cancer from the US FDA.
- Read more about FDA accepts for review NDA for sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalaemia
AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted a complete re-submission of a New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca. The FDA has indicated that this is a complete class 2 response.
- Read more about FDA Accept Teva’s Resubmitted NDA for SD-809 for Treatment of Chorea Associated with Huntington Disease
Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 3, 2017.
- Read more about Lilly's LARTRUVO™ (olaratumab) with Doxorubicin approved by FDA
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted approval of LARTRUVO™ (olaratumab injection, 10 mg/mL), in combination with doxorubicin, for the treatment of adults with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. LARTRUVO's indication is approved under Accelerated Approval, and is based on data from the Phase 2 portion of the pivotal JGDG trial. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
- Read more about Lannett submit Proposal to FDA Regarding Methylphenidate ER Tablets
Lannett Company, Inc. received a notice from the U.S. Food and Drug Administration (FDA) that it will seek to withdraw approval of the Company's Abbreviated New Drug Application (ANDA) for Methylphenidate Hydrochloride (HCl) Extended-Release (ER) Tablets.
- Read more about BTG submit “first patient in Malaysia receives TheraSphere radioembolisation therapy”
BTG plc, an international specialist healthcare company, announced that the first patient in Malaysia was treated with TheraSphere - a transarterial radioembolisation (TARE) therapy, which targets primary liver cancer and metastatic colorectal cancer with a powerful dose of radiation while minimising exposure to healthy tissue.
- Read more about Generics Expand into GI Markets, Spurring Growth : Reports
The generic versions of various expiring blockbuster drugs are keying growth in the gastrointestinal therapeutics and diagnostic markets. BCC Research reveals in its new report that biologic drugs, in particular, should drive growth in the GI over-the-counter market sector.